Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Роль комбинированной терапии в достижении целей лечения больных сахарным диабетом типа 2
Роль комбинированной терапии в достижении целей лечения больных сахарным диабетом типа 2
Петунина Н.А., Кузина И.А. Роль комбинированной терапии в достижении целей лечения больных сахарным диабетом типа 2. Consilium Medicum. 2013; 15 (4): 28–30.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Golay A, Ybarra J. Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2005; 19: 649–63.
2. Schnell O, Standl E. Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract 2006; 12 (Suppl. 1): 16–9.
3. Derosa G, Sibilla S. Optimizing combination treatment in the management of type 2 diabetes. Vasc Health Risk Manag 2007; 3 (5): 665–71.
4. Vaag AA. Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study. Endocr Pract 2006; 12 (Suppl. 1): 89–92.
5. Shimabukuro MT, Higa N, Takasu N. Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in type 2 diabetic patients. A randomized crossover study. J Diabetes Complications 2006; 20: 179–83.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 34). Lancet 1998; 352: 854–65.
7. Abdulkadir Alaa AA, Thanoon Imad AJ. Comparative Effects of Glibenclamide and Metformin on C-Reactive Protein and Oxidant/Antioxidant Status in Patients with Type II Diabetes Mellitus. Sultan Qaboos Univ Med J 2012; 12 (1): 55–61.
8. Marić A. Metformin – morethan gold standart in the treatment of type 2 diabetes mellitus. Diabetologia Croatica 2010; 39–3.
9. Кононенко И.В., Смирнова О.М. Роль Глюкованса в патогенетическом лечении сахарного диабета 2 типа. РМЖ. 2006; 13: 945–50.
10. Simonson DS. Effects of glyburideon in vivo insulin-mediatedglucosaedisposal. Am J Med 1990; 89: 47–50.
11. Карпов О.И. Микронизированный глибенкламид – модификация лекарственной формы и кинетики, нацеленная на результат. РМЖ. 2006; 26: 1940–3.
12. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
13. Ray JA, Huet D, Valentine WJ et al. Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance®) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting. Br J Diabetes Vasc Dis 2008; 8: 39.
14. Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. Clin Pharmacokinet 2002; 41 (15): 1301–9.
15. Lipska KJ, Bailey CJ, Inzucchi SE. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. Diabetes Care 2011; 34 (6): 1431–7.
16. Rogers M, Sands C, Self TH. Sulfonylurea-Induced Hypoglycemia: The Case Against Glyburide. Consultant 2011; 51 (2).
17. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. акад. РАН и РАМН И.И.Дедова, М.В.Шестаковой. 5-й выпуск. М., 2011.
18. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002; 19 (8): 673–80.
2. Schnell O, Standl E. Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract 2006; 12 (Suppl. 1): 16–9.
3. Derosa G, Sibilla S. Optimizing combination treatment in the management of type 2 diabetes. Vasc Health Risk Manag 2007; 3 (5): 665–71.
4. Vaag AA. Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study. Endocr Pract 2006; 12 (Suppl. 1): 89–92.
5. Shimabukuro MT, Higa N, Takasu N. Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in type 2 diabetic patients. A randomized crossover study. J Diabetes Complications 2006; 20: 179–83.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 34). Lancet 1998; 352: 854–65.
7. Abdulkadir Alaa AA, Thanoon Imad AJ. Comparative Effects of Glibenclamide and Metformin on C-Reactive Protein and Oxidant/Antioxidant Status in Patients with Type II Diabetes Mellitus. Sultan Qaboos Univ Med J 2012; 12 (1): 55–61.
8. Marić A. Metformin – morethan gold standart in the treatment of type 2 diabetes mellitus. Diabetologia Croatica 2010; 39–3.
9. Кононенко И.В., Смирнова О.М. Роль Глюкованса в патогенетическом лечении сахарного диабета 2 типа. РМЖ. 2006; 13: 945–50.
10. Simonson DS. Effects of glyburideon in vivo insulin-mediatedglucosaedisposal. Am J Med 1990; 89: 47–50.
11. Карпов О.И. Микронизированный глибенкламид – модификация лекарственной формы и кинетики, нацеленная на результат. РМЖ. 2006; 26: 1940–3.
12. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
13. Ray JA, Huet D, Valentine WJ et al. Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance®) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting. Br J Diabetes Vasc Dis 2008; 8: 39.
14. Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. Clin Pharmacokinet 2002; 41 (15): 1301–9.
15. Lipska KJ, Bailey CJ, Inzucchi SE. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. Diabetes Care 2011; 34 (6): 1431–7.
16. Rogers M, Sands C, Self TH. Sulfonylurea-Induced Hypoglycemia: The Case Against Glyburide. Consultant 2011; 51 (2).
17. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. акад. РАН и РАМН И.И.Дедова, М.В.Шестаковой. 5-й выпуск. М., 2011.
18. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002; 19 (8): 673–80.
Авторы
Н.А.Петунина, И.А.Кузина
Кафедра эндокринологии ФППОВ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
Кафедра эндокринологии ФППОВ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.